Kiora Pharmaceuticals, Inc.

We, along with Nasdaq, want to acknowledge the incredible leadership and contributions from our Chief Financial Officer, Melissa Tosca. The recent move to CFO follows the many successes in the capital markets, strategic planning, and building out the invaluable finance team at Kiora.

$KPRX ICYMI, view the fireside chat from the Canaccord Genuity Growth Conference between Brian Strem, Ph.D., and John Newman, Ph.D., CFA discussing KIO-301, KIO-104 and upcoming milestones for Kiora. https://lnkd.in/gGHFgBAc

Today we reported our 2nd quarter results showing the progress we've made across all business fronts this year. Notably, we finalized design of a Phase 2 study of KIO-301 in retinitis pigmentosa in partnership with Thea; advanced KIO-104 toward a Phase 2 trial in inflammatory retinal disease; and ended the quarter with $27.8 mm and an expected cash runway into 2027. We invite you to read More > https://lnkd.in/eSBnfNbH

Inspiring collaboration embracing diversity and creating a sense of belonging for children with low vision and blindness.

Chief Development Officer,, Eric Daniels, M.D., to present at the Jones Trading Healthcare Seaside Summit Mon., July 15 at 6:15 pm ET. Investors can access the latest update on our pipeline of drugs targeting retinal disease either live or by replay at the following link https://lnkd.in/eJHgpCrF

We are honored to welcome Lisa Walters-Hoffert to the Board of Directors at Kiora Pharmaceuticals. With decades of experience in biotech, Lisa will bring expertise in strategic development, governance, finance, and capital markets. Join us in welcoming Lisa on our journey to bring about new treatments for retinal diseases. https://lnkd.in/eNQQK3E7

Kiora welcomes Roger Goldberg, M.D., to its SAB. We look forward to the scientific insights and clinical perspectives he can bring to our development of new therapeutics for retinal diseases. https://lnkd.in/gESzb34X

We recently had the opportunity to present alongside like-minded innovators developing new treatment options for retinal disease. Listen below to our talk on our innovations for inherited and inflammatory retinal conditions. Thank you Ophthalmology Innovation Source https://lnkd.in/efvG23Uf

We would like to share additional MRI data from our ABACUS-1 study of KIO-301 reported from the ARVO medical conference this weekend. The presented data showed a statistically significant increase in brain activity in the visual cortex, as assessed by functional MRI, in patients with retinitis pigmentosa. Importantly, this increase was found to be time-dependent and demonstrated concordance with previously reported improvements in visual field, visual acuity, and functional vision. We invite you to review the full announcement and presentation here - https://lnkd.in/eB-8-BzE

There's a wonderful network of caregivers, doctors, nurses, families, and advocacy groups supporting greater independence to people who are blind or visually impaired. Today, we also want to recognize the incredible life of Trigger, a furry friend who fathered more than 300 guide dogs before retiring. https://lnkd.in/ewtpWQjF